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Recent work has shown that plasmid DNA can be efficiently encapsulated in well-defined ‘‘stabilized plasmid–lipid particles’’ (SPLP) that
have potential as systemic gene therapy vehicles [Gene Ther. 6 (1999) 271]. In this work, we examine the influence of ligands that enhance
cellular uptake on the transfection potency of SPLP. The ligand employed is a cationic poly(ethylene glycol) (PEG) lipid (CPL) consisting of a
lipid anchor and a PEG3400 spacer chain with four positive charges at the end of the PEG (CPL4). It is shown that up to 4 mol% CPL4 can be
inserted into preformed SPLP, resulting in up to 50-fold enhancements in uptake into baby hamster kidney (BHK) cells. The addition of Ca2 +
to SPLP-CPL4 (CPL4-incorporated SPLP) results in up to 10
6-fold enhancements in transgene expression, as compared to SPLP in the absence
of either CPL4 or Ca
2 +. These transfection levels are comparable to those observed for plasmid DNA–cationic lipid complexes (lipoplexes)
but without the cytotoxic effects noted for lipoplex systems. It is concluded that in the presence of Ca2 + and appropriate ligands to stimulate
uptake, SPLP are highly potent transfection agents.D 2003 Elsevier Science B.V. All rights reserved.Keywords: Liposome; Intracellular delivery; Gene therapy; SPLP; Calcium
1. Introduction vesicle [4] and exhibit extended circulation lifetimes andWork in this laboratory has focused on developing well-
defined non-viral vectors for systemic gene therapy applica-
tions. This work has been guided by studies on liposomal
systems containing anticancer drugs which have shown that
small (diameter < 100 nm), long circulating systems give
rise to preferential delivery to distal tumor sites following
intravenous (i.v.) injection [1–3]. We have therefore focused
on the development of small, long circulating liposomal
systems containing plasmid DNA. Techniques have been
developed that allow the efficient encapsulation of plasmid
DNA in well-defined ‘‘stabilized plasmid–lipid particles’’
(SPLP) of f 70 nm diameter that contain one plasmid per0005-2736/03/$ - see front matter D 2003 Elsevier Science B.V. All rights reserv
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E-mail address: pieterc@interchange.ubc.ca (P.R. Cullis).preferential accumulation of intact plasmid at distal tumour
sites following i.v. injection [5,6].
The levels of transgene expression observed at the tumour
site following i.v. injection of SPLP containing the luciferase
marker gene are superior to the levels that can be achieved
using either plasmid DNA–cationic liposome complexes
(lipoplexes) or naked DNA. However, for therapeutic bene-
fits, SPLP-mediated expression may still need to be
improved [5]. SPLP also exhibit low transfection potencies
in vitro [4]. These poor transfection properties may be due to
intrinsically low transfection potencies of the SPLP system
or may reflect low levels of uptake into cells [7]. Here, we
examine whether the insertion of ligands into SPLP that
leads to enhanced cell uptake can also enhance in vitro
transfection properties. Certain features of lipoplexes guided
the choice of the ligand to stimulate non-specific uptake into
cells. Cationic lipids in these lipoplexes facilitate electro-
static interactions between the negatively charged plasmid
DNA and the positively charged liposome to form theed.
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lipids also provide an overall positive charge that enhances
association of the complex with the negatively charged cell
membrane [8]. The absence of a positive charge on the
surface of the SPLP likely results in the reduced cellular
uptake as compared to lipoplexes. We have therefore synthe-
sized a series of cationic poly(ethylene glycol) (PEG) lipids
(CPL) designed for post-insertion into preformed SPLP to
impart a positive charge to the particle [9]. Previous work has
shown that CPL containing distearoyl-PE (DSPE) coupled to
PEG3400 containing a distal positive charge can be post-
inserted into preformed large unilamellar vesicles (LUV)
with the same lipid composition as SPLP, and that a CPL
containing four positive charges (CPL4) gives rise to max-
imum uptake of LUV-CPL into baby hamster kidney (BHK)
cells [10]. We show here that CPL4 can be inserted into
preformed SPLP and that the resulting SPLP-CPL4 exhibit
improved uptake and markedly improved transfection
potency in vitro.2. Materials and methods
2.1. Materials
1,2-Dioleoyl-3-phosphatidylethanolamine (DOPE) was
obtained from Northern Lipids (Burnaby, BC). 1,2-Dio-
leoyl-3-phosphatidylethanolamine-N-(Lissamine Rhod-
amine B Sulfonyl) (Rh-PE) and PicoGreen were obtained
from Molecular Probes (Eugene, OR). n,n-Dioleoyl-n,n-
dimethyl ammonium chloride (DODAC) was synthesized
and supplied by Dr. S. Ansell of Inex Pharmaceuticals
(Vancouver, BC). The PEG-CerC20 was synthesized as
indicated elsewhere [11] and was supplied by Dr. Z. Wang
of Inex. The pCMVLuc plasmid encodes the Photinus
pyralis luciferase gene under the control of the human
cytomegalovirus (CMV) early promoter and was supplied
by Dr. P. Tam of Inex. The pCMVGFP plasmid contains the
gene for the green fluorescent protein from Aequorea victo-
ria and was also supplied by Dr. P. Tam. DEAE-Sepharose
CL-6B, Sepharose CL-4B, octyl-h-D-galactoside, and
HEPES were obtained from Sigma-Aldrich (Oakville, ON).
Lipofectin was obtained from Gibco BRL (Burlington, ON).
BHK cells were obtained from Dr. R. MacGillivray of the
Department of Biochemistry and Molecular Biology, UBC.
2.2. Preparation of SPLP-CPL4
SPLP composed of DOPE:DODAC:PEG-CerC20
(84:6:10; mol%) and containing the plasmid pCMVLuc (or
pCMVGFP) were prepared according to the detergent dial-
ysis method of Wheeler et al. [4] using purification by anion
exchange (DEAE-Sepharose CL-6B) chromatography and
sucrose density gradient centrifugation to remove unencap-
sulated plasmid and empty vesicles, respectively. SPLP
containing Rh-PE were prepared by dissolving Rh-PE withother component lipids in CHCl3 at a molar ratio of 83.5:
10:6:0.5 (DOPE:DODAC:PEG-CerC20:Rh-PE) before form-
ing the lipid film.
CPL4 was inserted into preformed SPLP by incubating
SPLP (500 nmol lipid) with CPL4 (12.5, 19, and 30 nmol) at
60 jC for 2–3 h in HEPES-buffered saline (HBS), pH 7.5,
unless otherwise indicated. The integrity of plasmid DNA
following CPL4 insertion was assayed by Southern analysis
as described below. Unincorporated CPL4 was removed by
gel filtration chromatography on a Sepharose CL-4B column
equilibrated in HBS. Fractions (1 ml) were collected and
assayed for CPL4, phospholipid, and DNA content. Frac-
tions containing all three components were pooled and
concentrated. CPL4 content was determined by the fluores-
cence of the dansyl labeled CPL at kem 510 nm following
excitation at kex 340 nm employing a Perkin Elmer LS52
Luminescence spectrophotometer. A standard curve was
derived from a stock solution of dansylated CPL in HBS.
For SPLP containing Rh-PE, the phospholipid content was
determined from the fluorescence of the Rh label measured
at kem 590 nm following excitation at kex 560 nm, using
excitation and emission slit widths of 10 and 20 nm,
respectively. For SPLP that did not contain the Rh label,
phospholipid was determined using the method of Fiske and
Subbarow [12], following lipid extraction according to Bligh
and Dyer [13]. Plasmid DNA was determined using the
PicoGreen Assay kit (Molecular Probes) as previously
described [16]. For the Rh-PE-containing systems, the incor-
poration of CPL4 was determined by dividing the dansyl to
rhodamine ratio before the Sepharose column by the ratio
after the column multiplied by 100%. For the other systems,
incorporation was determined by dividing the CPL4 content
by the total lipid content and multiplying by 100%.
Lipoplexes were prepared at a charge ratio of 1.5:1
(positive-to-negative) by adding 25 Al of 88 Ag/ml plasmid
DNA (pCMVLuc or pCMVGFP) to 25 Al of DOPE:DODAC
LUV (0.8 mM) in distilled water while vortexing, followed
by incubation at room temperature for 30 min before addition
to cells. Lipofectin lipoplexes were similarly prepared.
Mean vesicle diameters were determined by quasi-elastic
light scattering (QELS) using a Nicomp Model 270 Sub-
micron Particle Sizer (PSS, Santa Barbara, CA). Freeze-
fracture electron microscopy studies were performed as
described by Wheeler et al. [4]. SPLP diameters were
obtained from the population of particles exhibiting equato-
rial fracturing [14], or from all the particles using the size
correction method of Hallett et al. [15].
DNA for Southern analysis was extracted using a phenol/
chloroform extraction following incubation of SPLP systems
with 50% mouse serum. The resulting DNA was then
subjected to electrophoresis through a 1% agarose gel,
transferred to a nylon membrane (Amersham, Piscataway,
NJ) and subjected to Southern analysis. The membrane was
exposed to random-primed 32P-labelled PvuII restriction
fragment from the luciferase gene according to current
protocols. Hybridization intensities were quantified using a
L.R. Palmer et al. / Biochimica et Bioph206Phosphorimagerk SI from Amersham Biosciences (Piscat-
away, NJ). The data were converted to give amounts of intact
DNA relative to undigested DNA.
Levels of PEG-CerC20 and DOPE were determined by
HPLC analyses performed by Northern Lipids Inc.Fig. 1. Insertion protocol for the production of SPLP-CPL4. (A) Structure of dans
molecule attached to a lipid anchor, DSPE. (B) Protocol for insertion of CPL4 in
DODAC (black headgroups), and PEG-CerC20 (lipids with attached polymer). The
CPL4 monomers transfer from micelles and insert into the external monolayer of
column chromatography. For further details, see Materials and methods. Reproduc
particles: a systemic gene therapy vector, Methods Enzymol. 346 (2001) 36–71.2.3. Uptake and transfection studies
A transformed BHK cell line (tk) was used for all uptake
and transfection studies. To determine the cellular uptake of
SPLP, 1105 BHK cells were seeded in each well of a 12-
ysica Acta 1611 (2003) 204–216ylated CPL4. CPL4 possesses four positive charges at the end of a PEG3400
to preformed SPLP. The SPLP are composed of DOPE (light headgroups),
SPLP and CPL4 are incubated together at 60 jC for 3 h, during which time
SPLP. Unincorporated CPL4 is subsequently removed by Sepharose CL-4B
ed from D.B. Fenske, I. MacLachlan, P.R. Cullis, Stabilized plasmid– lipid
Copyright 2001 Academic Press.
Fig. 2. Time course for the insertion of CPL4 into SPLP at 60 jC. Dansylated
CPL4 (0.3 Amol) was added to SPLP composed of 6 Amol DOPE:PEG-
CerC20:DODAC:Rh-PE (83.5:10:6:0.5; mol%) containing 360 Ag
pCMVLuc in a total volume of 1.5 ml and incubated at 60 jC. Aliquots
(250 Al) of the mixture were taken at the times indicated and unincorporated
CPL4 subsequently removed by Sepharose CL-4B column chromatography.
CPL4 incorporation was determined as described in Materials and methods.
Fig. 3. Effect of cation concentration on the de-aggregation of SPLP
following insertion of CPL4. SPLP were prepared and 4 mol% CPL4 was
inserted as described in Materials and methods. The mean diameter and
standard deviation of the mean diameter of the SPLP-CPL4 in the presence
of increasing concentrations of Ca2 + (.) and Mg2 + (n) were determined by
QELS. CaCl2 or MgCl2 from 500 mM stock solutions was added to SPLP-
CPL4 (180 nmol in 400 Al). The addition of Ca2 + or Mg2 + results in a more
monodisperse preparation as indicated by a reduction in the standard
deviation of the mean diameter at cation concentrations above 30 mM.
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[Dulbeco’s modified Eagle’s media (DMEM) containing
10% fetal bovine serum (FBS)] at 37 jC in 5% CO2. SPLP
and SPLP-CPL4 were prepared in HBS containing 40 mM
CaCl2 and 200 Al of these preparations was mixed with 800
Al of complete media at a final lipid dose of 20 AM and added
to the cells. DOPE:DODAC lipoplexes were prepared as
indicated above and aliquots of 200 Al were again mixed
with 800 Al of complete media (final lipid dose 20 AM) and
added to the cells. Final plasmid DNA concentrations were
1.4 and 2.2 Ag/ml for the SPLP systems and the lipoplexes,
respectively. Cells were incubated at 37 jC for the indicated
period, washed twice with phosphate-buffered saline (PBS),
and lysed with 600 Al of lysis buffer (0.1% Triton X-100 in
250 mM sodium phosphate, pH 7.5). Rhodamine fluores-
cence was determined using a kex of 560 nm and a kem of 600
nm. An emission filter of 530 nm was also used. Lipid uptake
was determined by comparison of the fluorescence in the
lysate to that of a lipid standard and normalized to the cell
number as determined by the BCA protein assay (Pierce,
Rockford, IL). Where indicated, fluorescence micrographs
were obtained using an Axiovert 100 Zeiss fluorescent
microscope (Carl Zeiss, Jena) using a rhodamine filter from
Omega Opticals (Brattleboro, VT).
The effects of Ca2 + and Mg2 + on lipid uptake were
determined as described above with minor modifications.
BHK cells (5 104 per well) were seeded in a 24-well plate
in 1 ml of complete media and incubated overnight at 37 jC.SPLP-CPL4 (40 nmol) were prepared in HBS and appropri-
ate amounts of CaCl2 or MgCl2 added (total volume 100 Al).
Complete media (400 Al) were added to the SPLP-CPL4
resulting in final cation concentrations of 4–14 mM. This
mixture was then added to the cells and incubated for 4 h at
37 jC. Cells were then washed twice with PBS and lysed in
600 Al of lysis buffer (0.1% Triton X-100 in 250 mM sodium
phosphate, pH 7.5).
Unless otherwise indicated, transfection studies were
performed employing 1104 BHK cells plated in each well
of a 96-well plate in 150 Al complete media before overnight
incubation at 37 jC in 5% CO2. SPLP and SPLP-CPL4
corresponding to 0.5 Ag of pCMVLuc in 20 Al HBS (SPLP),
or HBS containing 40 mM CaCl2 (SPLP-CPL4) were added
to 80 Al of complete media for a plasmid concentration of 5.0
Ag/ml. A transfection time of 4 h with a total incubation time
of 24 h was used routinely. The transfection time is defined
as the time the cells are incubated with the plasmid-contain-
ing particles, whereas the total incubation time includes the
transfection time (after which the transfection media is
replaced) plus the subsequent time for which the cells are
incubated before assaying for transgene expression. After 24
h, the cells were lysed with 100 Al of lysis buffer, and 40 Al of
the lysate was transferred to a 96-well luminescence plate.
Luciferase activity was determined using a Luciferase reac-
tion kit (Promega, Madison, WI), a luciferase standard
(Boehringer-Mannheim), and a ML3200 microtiter plate
luminometer from Molecular Dynamics (Chantilly, VA).
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by the BCA protein assay.
The transfection time course study included SPLP, SPLP-
CPL4, and Lipofectin (Gibco BRL) and DOPE/DODAC
lipoplexes containing pCMVLuc. After transfection times
of 4, 8, and 24 h, the transfection media were removed and,
in the case of the 4- and 8-h transfections, replaced with
complete media for a total incubation time of 24 h. At 24 h,
all cells were lysed and assayed for luciferase activity and
protein content (BCA assay).
SPLP-CPL4, DOPE:DODAC lipoplexes, and Lipofectin
lipoplexes containing pCMVGFP were prepared as
described for pCMVLuc. The transfections were performed
as described above at a plasmid DNA dose of 5.0 Ag/ml.
Following incubation of the samples for 24 and 48 h, the
transfection media were removed, the cells were washed, and
fresh media added. The cells were then viewed under theFig. 4. Freeze-fracture electron micrographs of (A) SPLP, (B) SPLP-CPL4, and
prepared as described in Materials and methods, and contained 4 mol% CPL4. TZeiss fluorescence microscope. The number of cells express-
ing GFP were counted using a fluorescein filter (Omega
Opticals). The transfection efficiency was expressed as
percentage of cells expressing GFP.3. Results
3.1. Cationic PEG lipids can be inserted into preformed
SPLP
Previous work has shown that SPLP exhibit lower uptake
into cells and much lower transfection potencies than lip-
oplexes [16]. It has also been shown that surface-associated
CPLs, particularly those containing four charges at the end of
the PEG molecule (CPL4; for structure, see Fig. 1A), can
dramatically enhance the uptake of LUV into cells [10].(C) SPLP-CPL4 in the presence of 40 mM CaCl2. The SPLP-CPL4 was
he bar in plate A corresponds to 312 nm.
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compositions similar to SPLP employing a straightforward
incubation protocol [10]. We first examined whether a
similar procedure could be developed to insert CPL4 into
SPLP. SPLP containing pCMVLuc were prepared by the
detergent dialysis procedure of Wheeler et al. [4] from a lipid
mixture containing 6 mol% of the cationic lipid DODAC, 84
mol% of the fusogenic helper lipid DOPE, and 10 mol% of a
stabilizing lipid consisting of PEG2000 attached to a ceramide
(Cer) anchor (PEG-Cer). The ceramide anchor of the PEG-
Cer contained a C20 acyl chain (PEG-CerC20) that does not
readily exchange out of the vesicle, thus contributing to a
highly stable SPLP system [4]. The detergent dialysis pro-
cedure results in the formation of a mixture of SPLP
containing one plasmid per vesicle, free plasmid, and empty
vesicles. SPLP were purified by removing free plasmid and
empty vesicles by DEAE column chromatography and den-
sity centrifugation, respectively, as described elsewhere [4].
The procedure for post-insertion of CPL4 into the pre-
formed SPLP is illustrated in Fig. 1B. Purified SPLP were
incubated with CPL4 (f 5 mol%) at 60 jC for up to 3 h and
then separated from non-incorporated CPL4 by column
chromatography. As shown in Fig. 2, this resulted in associ-
ation of up to 80% of the available CPL4 with the SPLP,
corresponding to 4 mol% of the total lipid in the SPLP-CPL4
system.
3.2. SPLP-CPL4 aggregate following insertion of CPL4 and
de-aggregate following addition of divalent cations
Previous work has shown that vesicles containing CPL
tend to aggregate and that this aggregation can be inhibited
by increasing the ionic strength of the medium [10]. It was
found that SPLP-CPL4 were also susceptible to aggregation,Fig. 5. Serum stability of SPLP-CPL4 as assayed by Southern analysis of encapsula
mol% of CPL4 inserted using the post-insertion protocol. SPLP-CPL4 containing 5
for the times indicated, an aliquot of the mixture corresponding to 1 Ag of plasm
Southern analysis, as described in the Materials and methods. Lanes 1–4 indicate
times, respectively; Lanes 5–8 indicate the behaviour of plasmid extracted from
behaviour of plasmid DNA extracted from SPLP containing 4 mol% CPL4 followand that this aggregation could be reversed by adding NaCl,
CaCl2, or MgCl2 to the SPLP-CPL4 formulation. This effect
is illustrated in Fig. 3, which shows the effect of the addition
of CaCl2 or MgCl2 on aggregation of SPLP-CPL4 as moni-
tored by the change in the standard deviation of the mean
diameter of the particles, as measured by quasi-elastic light
scattering (QELS). For both cations the standard deviation
decreased with increasing cation concentration, with optimal
de-aggregation occurring above 30 mM. This behaviour
could also be visualized by freeze-fracture electron micro-
scopy. As shown in Fig. 4A, freeze-fracture micrographs of
SPLP reveal small monodisperse particles, whereas SPLP-
CPL4 prepared in the absence of CaCl2 are highly aggregated
(Fig. 4B). As shown in Fig. 4C, the addition of 40 mMCaCl2
reverses this aggregation to produce monodisperse particles
similar to the SPLP preparation. It may be noted that this
process is reversible in that the subsequent removal of the
CaCl2 by dialysis results in re-aggregation (data not shown).
The sizes of SPLP and SPLP-CPL4 in the presence of
CaCl2 were compared using QELS and freeze-fracture elec-
tron microscopy. QELS studies revealed the mean diameter
of SPLP and SPLP-CPL4 to be 80F 19 and 76F 15 nm,
respectively, whereas the freeze-fracture studies indicated
diameters of 68F 11 and 64F 14 nm. These values for SPLP
diameters are in close agreement with previous studies [4].
3.3. PEG-CerC20 content and stability of SPLP-CPL4
The observation that CPL4 can be inserted to achieve
levels as high as 4 mol% of the total SPLP lipid indicates that
the level of CPL4 in the outer monolayer of the SPLP-CPL4
is 8 mol%. Given that the initial concentration of PEG-
CerC20 is 10 mol%, this suggests that the total levels of PEG-
lipids in the outer monolayer of the SPLP-CPL4 canted plasmid. SPLP were prepared as indicated in the legend to Figs. 2 and 4
Ag pCMVLuc were incubated in the presence of 50% mouse serum at 37 jC
id DNA was removed and plasmid DNA was extracted and subjected to
the behaviour of naked plasmid DNA following 0, 1, 2, and 4 h incubation
SPLP following 0, 1, 2, and 4 h incubation times; Lanes 9–12 show the
ing 0, 1, 2, and 4 h incubation times.
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observations showing that PEG(2000)-lipids can reach con-
centrations as high as 17.5 mol% in DOPE bilayers [17].
Nevertheless, these levels are higher than the levels of PEG-
lipids that can usually be incorporated into phosphatidylcho-
line lipid vesicles [18], leading to the possibility that some of
the PEG-CerC20 in the outer monolayer exchanged out as
CPL4 was inserted. This was examined by HPLC by meas-
uring the ratio of PEG-CerC20-to-DOPE for the SPLP before
and after insertion of CPL4. CPL4 was inserted into SPLP as
described previously. Analysis following removal of non-
incorporated material determined that 4 mol% CPL4 (nor-
malized to the total SPLP lipid) was inserted into the SPLP.
Before insertion of the CPL4, the PEG-CerC20-to-DOPE
ratio was 0.091, corresponding to a PEG-CerC20 content of
7.6 mol% (assuming that the DOPE constituted 84 mol% of
the lipid content). Following insertion of the CPL4, the PEG-
CerC20-to-DOPE ratio was found to be 0.072, indicating a
PEG-CerC20 content of 6.0 mol%. Assuming that all of the
PEG-CerC20 lost from the SPLP during insertion of the CPL4
is lost from the outer monolayer, this indicates that the PEG-
CerC20 content of the outer monolayer decreases from 7.6 to
4.4 mol% during the insertion process. The total PEG-lipid
content in the outer monolayer of the SPLP-CPL4 can then
be estimated to be 12.4 mol%.
The stability of SPLP and SPLP-CPL4 following incuba-
tion in 50% mouse serum for up to 4 h is illustrated in Fig. 5.
In all cases, the encapsulated plasmid DNA was fully pro-
tected from serum degradation. In contrast, essentially com-
plete degradation of the plasmid in lipoplexes was observed
within 30 min of incubation in serum (data not shown).
3.4. SPLP-CPL4 exhibit enhanced uptake into BHK cells
and dramatically enhanced transfection potency
The next set of experiments was aimed at determining the
influence of incorporated CPL4 on the uptake of SPLP into
BHK cells and the resulting transfection potency of the
SPLP-CPL4 system. SPLP containing up to 4 mol% CPL4
were prepared in the presence of 40 mM CaCl2 and were
added to BHK cells (final CaCl2 concentration 8 mM) andFig. 6. (a) Influence of the amount of CPL4 incorporated into SPLP on the
association (binding/uptake) of SPLP-CPL4 with BHK cells. Uptake of
SPLP containing 0 (.), 2 (n), 3 (E), or 4 (x) mol% CPL4 was
investigated; the uptake of DOPE:DODAC lipoplexes (o) is given for
comparison. The insertion of CPL4 into SPLP and the preparation of
lipoplexes was performed as described in Materials and methods. The
SPLP-CPL4 media contained 40 mM CaCl2 to prevent aggregation, with
addition to the BHK cells resulting in dilution of the CaCl2 concentration to
8 mM. The uptake protocol involved incubation of SPLP-CPL4 (20 AM
total lipid) with 105 BHK cells in DMEM containing 10% FBS. Following
incubation, the cells were lysed and uptake of rhodamine-PE was measured
as described in Materials and methods. (b) Fluorescence micrographs of
BHK cells following uptake of SPLP (Panel I) and SPLP containing 4
mol% CPL4 (Panel II) following a 4-h incubation. The micrographs on the
left were taken in the phase contrast mode and those on the right in the
(rhodamine) fluorescence mode.
Fig. 8. Influence of Ca2 + (.) and Mg2 + (n) on the transfection potency of
SPLP-CLP4. SPLP-CPL4 containing 4 mol% CPL4 were prepared by the
post-insertion process as described in Materials and methods. Increasing
concentrations of CaCl2 or MgCl2 were added to the SPLP-CPL4 (5.0 Ag
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associated SPLP-CPL4 as indicated in Materials and meth-
ods. As shown in Fig. 6a, uptake of SPLP that contain no
CPL4 is minimal even after 8 h of incubation. However,
uptake is dramatically increased for SPLP containing 3
mol% or higher levels of CPL4. For example, SPLP con-
taining 4 mol% CPL4 exhibit accumulation levels at 8 h that
are approximately 50-fold higher than those achieved by
SPLP in the absence of CPL. This enhanced uptake is
visually illustrated in Fig. 6b, which shows fluorescence
micrographs of BHK cells following incubation with rhod-
amine-labeled SPLP and SPLP-CPL4 for 4 h.
The transfection properties of SPLP, SPLP-CPL4, and
plasmid DNA-cationic liposome lipoplexes (DODAC/
DOPE; 1:1) were examined using the transfection protocol
described in Materials and methods. This protocol involves
incubation of BHK cells with SPLP or lipoplexes for 4 h (the
transfection time) followed by replacement of media and
further incubation to maximize transgene expression. The
total incubation time (transfection time plus time of incuba-
tion following the media change) was kept constant at 24 h.
As shown in Fig. 7, the presence of increasing amounts of
CPL4 resulted in dramatic increases in the transfection
potency of the SPLP system. SPLP-CPL4 containing 4
pCMVLuc/ml), transferred to BHK cells, and incubated for 48 h in DMEM
containing 10% FBS. The cells were then lysed and the luciferase activity
and protein content measured as described in Materials and methods.
Fig. 9. Effect of Ca2 + (.) and Mg2 + (n) on the association (binding/
uptake) of SPLP-CPL4 with BHK cells. SPLP-CPL4 were prepared with
increasing cation concentration as indicated for Fig. 8 and incubated with
BHK cells (f 80 AM lipid and f 5.0 Ag pCMVLuc/ml per well) for 4 h in
DMEM containing 10% FBS. The cells were then lysed and the SPLP-
CPL4 content (as indicated by the Rh-PE lipid label) and cellular protein
measured as described in Materials and methods.
Fig. 7. Luciferase expression in BHK cells following transfection by SPLP
containing various amounts of CPL4. SPLP containing 2, 3, and 4 mol%
CPL4 were prepared employing the post-insertion process. BHK cells (10
4)
were transfected with SPLP, SPLP-CPL4, and DOPE:DODAC (1:1)
lipoplexes containing 5.0 Ag/ml pCMVLuc using a transfection time of 4
h and a complete incubation time of 24 h, as described in Materials and
methods. The CaCl2 concentration in the SPLP-CPL4-containing systems
following dilution with media and addition to the BHK cells was 8 mM.
After transfection, the cells were lysed and the luciferase and BCA assays
performed as described in Materials and methods.
Fig. 10. Luciferase expression in BHK cells as a function of transfection
time for SPLP, SPLP-CPL4, and lipoplexes. SPLP-CPL4 containing 4 mol%
CPL4 were prepared by the post-insertion process. BHK cells in DMEM
and 10% FBS were incubated with SPLP, SPLP-CPL4, and lipoplexes (5.0
Ag/ml pCMVLuc) employing transfection times of 4, 8, and 24 h and total
incubation times of 24 h. The final CaCl2 concentration following addition
of media was 8 mM. The cells were then assayed for luciferase activity and
protein content. Luciferase activity following transfection with SPLP-CPL4
(.), SPLP (z), DOPE:DODAC lipoplexes (n), and Lipofectin lipoplexes
(x) is plotted as a function of transfection time. Lipoplexes were prepared at
a charge ratio of 1.5:1.
Fig. 11. (A) The transfection potency of SPLP (z), SPLP-CPL4 (.) con-
taining 4 mol% CPL4, and Lipofectin lipoplexes (x) following extended
transfection times with BHK cells. SPLP-CPL4 and lipoplexes were
generated as indicated for Fig. 10. BHK cells were transfected in DMEM
containing 10% FBS for 24 and 48 h with SPLP-CPL4 and Lipofectin
lipoplexes (charge ratio of 1.5:1) containing 5.0 Ag/ml pCMVLuc.
Following transfection, the luciferase expression levels and cell protein
levels were determined in the cell lysate. The luciferase activity was
normalized for protein content in the lysate and plotted as a function of
transfection time. (B) The toxicity of SPLP-CPL4 (.) containing 4 mol%
CPL4 and Lipofectin lipoplexes (x) as a function of transfection time, as
assayed by cell survival based on the protein concentration in the cell lysate.
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3 103 times higher than those attained with SPLP.
3.5. Ca2+ is required for transfection activity of SPLP-CPL4
Previous work has shown that the transfection potency of
SPLP is highly sensitive to the presence of Ca2 +, where the
presence of f 10 mM Ca2 + enhances transfection potency
several hundred-fold [19]. It was therefore of interest to
determine the influence of Ca2 + on the transfection activity
of SPLP-CPL4. SPLP containing 4 mol% CPL4 were incu-
bated with BHK cells for 48 h in the presence of varying
amounts of MgCl2 or CaCl2 and the luciferase activities were
determined. As shown in Fig. 8, the transfection activity was
almost completely dependent on the presence of Ca2 + in the
transfection medium. At the optimum CaCl2 concentration
of 10 mM, SPLP-CPL4 exhibited transfection potencies that
were more than 105 times higher than if the corresponding
amount of MgCl2 was present.
To determine whether the different transfection properties
of SPLP-CPL4 in the presence of Ca
2 + or Mg2 + could be
accounted for by differences in cellular uptake, the accumu-
lation of SPLP-CPL4 into BHK cells was monitored follow-
ing a 4-h incubation in the presence of MgCl2 or CaCl2. As
shown in Fig. 9, uptake of SPLP-CPL4 into BHK cells is thesame for both Ca2 + and Mg2 +. It may be noted that SPLP-
CPL4 uptake decreases slightly as the concentration of
divalent cations increases, likely due to the shielding of the
negatively charged CPL4 binding sites on the surface of BHK
cells. These results are consistent with a previous study
indicating that Ca2 + has little effect on the cellular uptake
of SPLP [19].
3.6. SPLP-CPL4 exhibit transfection potencies in vitro that
are comparable to or greater than the transfection potencies
of lipoplexes
The data presented in Fig. 7 indicate that DOPE/DODAC
lipoplexes yield f 100-fold higher levels of gene expres-
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period of 4 h. Given that SPLP-CPL4 are stable systems,
uptake can conceivably continue over extended time periods.
We therefore examined the transfection levels achieved when
SPLP-CPL4 or the lipoplexes were applied to BHK cells for
transfection times of 4, 8, and 24 h. Two types of lipoplexes
were used, namely, DOPE:DODAC (1:1) lipoplexes (charge
ratio 1.5:1) and lipoplexes generated using the transfection
reagent Lipofectin, consisting of DOPE/DOTMA (1:1) lip-
oplexes at a charge ratio of 1.5. As shown in Fig. 10, the
potency of SPLP-CPL4 increases markedly with increased
transfection times, suggesting that the rate of uptake of the
SPLP-CPL4 system is still a limiting factor for transfection.
For the 24-h transfection time, where the cells are assayed for
luciferase expression immediately after the transfection
period, transfection levels are comparable to those achieved
by Lipofectin or the DOPE/DODAC lipoplexes.
Further experiments were conducted to determine trans-
fection levels after 24 or 48 h with SPLP-CPL4 and lip-
oplexes where luciferase activities were assayed immedi-Fig. 12. Fluorescence and phase-contrast micrographs of BHK cells transfected w
were transfected with SPLP-CPL4 for 24 h (A1, A2) and 48 h (B1, B2) and wi
pCMVGFP as described in Materials and methods. SPLP-CPL4 containing 4 mo
resulting in an 8-mM CaCl2 concentration in the transfection medium. BHK cells
containing 10% FBS for the 24- and 48-h transfection times and examined immeately following the transfection period. The activity of
Lipofectin (DOPE:DOTMA) lipoplexes leveled off at
f 2000 ng luciferase/mg cell protein after 24 h (Fig. 11A).
Similar results were obtained for the DOPE:DODAC lip-
oplexes (data not shown). In contrast, the activity of the
SPLP-CPL4 formulation continued to increase as the incu-
bation time was increased, achieving luciferase expression
levels corresponding to 4000 ng/mg cell protein at 48 h. This
activity is approximately 106 times higher than observed for
SPLP (in the absence of Ca2 +) and almost double the levels
that can be achieved by Lipofectin lipoplexes.
3.7. SPLP-CPL4 are non-toxic and efficient transfection
agents
It is well known that lipoplexes can be toxic to cells. The
SPLP-CPL4 contain low levels of cationic lipid and are
potentially less toxic than lipoplexes. The toxicities of
SPLP-CPL4 and lipoplexes were assayed by determining
cell viability following a 24- or 48-h exposure to levels ofith SPLP-CPL4 and lipoplexes containing a plasmid coding for GFP. Cells
th Lipofectin for 24 h (C1, C2). SPLP and lipoplexes were prepared with
l% CPL were prepared by the post-insertion process and contained CaCl2,
(105) were incubated with SPLP-CPL4 or Lipofectin (5.0 Ag/ml) in DMEM
diately after the transfection period.
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mid, and a total lipid dose of approximately 80 and 45 AM
for SPLP-CPL4 and lipoplexes, respectively. As shown in
Fig. 11B, SPLP-CPL4 exhibited little toxicity, whereas lip-
oplexes were highly toxic. Cell survival was only 30% after a
48-h incubation with Lipofectin lipoplexes, whereas f 95%
of the cells were viable following a 48-h incubation with
SPLP-CPL4.
Studies were also conducted to determine the efficiency
of transfection as indicated by the proportion of cells trans-
fected by SPLP-CPL4. The proportion of transfected cells
was determined by employing plasmid containing the green
fluorescent protein (GFP) gene. GFP expression was
detected by fluorescence microscopy. As shown in Fig.
12A and B, approximately 55% of the cells at 24 h and
70% at 48 h were transfected by SPLP-CPL4, with no
apparent cell death. In contrast, Lipofectin lipoplexes exhibit
maximum transfection efficiencies of about 35% with only
f 50% cell survival after the 24-h transfection period (Fig.
12C). Similar low transfection efficiencies and high toxic-
ities were also seen with DOPE:DODAC lipoplexes (data
not shown).4. Discussion
This study demonstrates that the incorporation of CPL4
into preformed SPLP results in both improved uptake into
BHK cells and dramatically enhanced transfection potencies
when Ca2 + is present. There are three points of interest. The
first concerns the post-insertion process itself and the chem-
ical composition and structure of the SPLP-CPL4 system
following insertion of CPL into preformed SPLP. The second
concerns the mechanism whereby the CPL increases the
transfection potency of the SPLP vector. Finally, it is of
interest to discuss the implications of these results for the
design of SPLP that have improved properties as a systemic
gene therapy system. We discuss these areas in turn.
The results presented here demonstrate that the cationic
PEG lipid CPL4 can be inserted into preformed SPLP
employing a simple process involving incubation at 60 jC.
It is likely that this procedure offers a general method for
modifying the tropism and transfection potency of SPLP by
post-insertion of PEG-lipids containing ligands that promote
targeting and intracellular delivery. The ability to insert CPL4
to levels corresponding to 8 mol% of the total lipid in the
SPLP outer monolayer correlates well with results of Uster et
al. [20]. They demonstrated that PEG-PE can be inserted into
preformed LUV by employing a similar incubation protocol,
resulting in systems that exhibit extended circulation life-
times [20]. It is also consistent with previous results from this
laboratory showing that CPL4 can be inserted into preformed
LUV with a lipid composition similar to the SPLP system
[10]. The total levels of PEG-lipids achieved in the outer
monolayer (12.4 mol%) are less than the maximum levels
that can be accommodated by DOPE bilayers (17.5 mol%)[17]. Although the maximum levels of incorporation of
PEG-lipids into LUVs containing phosphatidylcholine are
somewhat lower, usually by 7–10 mol% [18], a number of
authors have reported that levels as high as 15 mol% can be
achieved before lytic effects are observed [21–23].
The tendency for the SPLP-CPL4 system to aggregate
following insertion of the CPL4 is consistent with previous
observations that LUV containing CPL4 also aggregate [10].
The reason for this aggregation is not currently understood;
however, two general points can be made. First, the inter-
action is likely due to electrostatic interactions between
vesicles, given the inhibition of aggregation at higher ionic
strengths. Second, the aggregation is not a consequence of the
post-insertion process itself, because aggregation is also
observed for LUV that contain CPL4 in the original lipid
mixture from which the LUV were formed [10]. One possi-
bility is that H-bonding between the amino and carbonyl
groups present in the distal headgroups leads to interactions
between apposed membranes with subsequent aggregation.
The second point of discussion concerns the mechanism
whereby CPL4 increases the transfection potency of the
SPLP system. The results presented here indicate that these
improvements arise, at least in part, from dramatically
improved uptake into cells. In this regard, a number of
studies have indicated that the cationic lipids contained in
lipoplex systems play a direct role in stimulating uptake into
cells [24] and that this uptake arises due to the positive
charge on the lipoplexes [25]. It has been suggested that
heparin sulfonated proteoglycans on the cell surface play a
primary role in this process [26,27]. Enhanced uptake of
SPLP following addition of the CPL4 could be attributed to
similar mechanisms, although the increase in transfection
potency is largely dependent on the additional presence of
Ca2 +. Previous work has shown that the presence of Ca2 +
results in a maximum increase in SPLP transfection potency
of f 600-fold and that this increase is derived from the
ability of Ca2 + to assist in destabilizing the endosomal
membrane following uptake, rather than from an increase
in uptake [19]. It could therefore be suggested that the
observed improvements in transfection potency of SPLP-
CPL4 are the result of improvements in uptake mediated by
the CPL4 coupled with the enhanced ability to destabilize the
endosomal membrane due to the presence of Ca2 +. In this
regard, the transfection potency of SPLP-CPL4 (in the
presence of Ca2 +) is increased by a factor of f 104 (Fig.
7), for a 4-h incubation, in comparison to the transfection
potency of SPLP in the absence of Ca2 +. This could be
accounted for by an increase in uptake of SPLP into BHK
cells by approximately 50-fold due to the presence of 4
mol% CPL4 (Fig. 6A, 4 h incubation) multiplied by a factor
of f 600 due to the presence of Ca2 +.
The final area of discussion concerns the implications of
the results presented here for the design of next-generation
SPLP that exhibit improved transfection properties following
i.v. administration. First, it should be noted that the SPLP-
CPL4 system described here is unlikely to be of direct utility
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employed contains a PEG3400 linker, and thus the cationic
groups at the end of the PEG will extend beyond the PEG2000
‘cloud’ provided by the PEG-Cer components of the SPLP.
Charged liposomal systems are rapidly cleared from the
circulation following i.v. administration [28], and it would
therefore be expected that the SPLP-CPL4 described here
would not exhibit the long circulation lifetimes that lead to
accumulation at disease sites such as tumours. Strategies that
could overcome this difficulty include the possibility of
inserting CPL containing a shorter PEG linker, such as
PEG1000. The positive charge should then be shielded by
the PEG2000 of the PEG-Cer, leading to longer circulation
lifetimes. A remaining problem concerns the need to achieve
exposure of the CPL after arrival at the target site to stimulate
uptake into cells. As we have noted elsewhere, the PEG
cloud on the SPLP can be designed to dissociate over a time
determined by the length of the acyl chain contained in the
ceramide anchor [4]. If the SPLP PEG-Cer is designed to
dissociate slowly, a situation can be envisioned where SPLP
that have accumulated at a disease site such as a tumour will
lose the PEG shield, thus exposing the CPL which promote
uptake. An alternative possibility is to post-insert lipids
containing specific targeting ligands, which do not stimulate
clearance, at the end of the PEG linker.
The strong Ca2 + dependence of the transfection proper-
ties of the SPLP and SPLP-CPL systems also represents a
challenge to translate into improved transgene expression in
vivo, as it is unlikely that systemic Ca2 + levels of 8 mM can
be achieved. Two possibilities are to generate local high
concentrations of Ca2 + or to deliver factors with the SPLP
that can substitute for Ca2 +. Local high concentrations of
Ca2 + could theoretically be achieved by co-encapsulating
Ca2 + in the SPLP system; however, initial attempts in this
regard have not led to enhanced in vitro expression [19]. It is
possible that higher entrapped Ca2 + levels or increased
leakage rates may lead to improved properties. Alternatively,
it may be possible to reduce the need for Ca2 + by using
SPLP with increased levels of cationic lipid [29,30]. Ca2 +
and cationic lipids act together to destabilize the endosomal
membrane [19], and the magnitude of the Ca2 + effect is less
pronounced for systems such as lipoplexes that contain
higher levels of cationic lipids [31]. This difference in
cationic lipid content is substantial as illustrated by a simple
calculation, which assumes that lipoplexes have an internal
structure consisting of lipid bilayers of 4 nm thickness
sandwiching plasmid DNA in an interlamellar space 2.5
nm thick as indicated by X-ray studies [32]. If cationic lipids
exhibit a surface area of 0.6 nm2 (comparable to diacylphos-
pholipids [33]), a 100-nm-diameter lipoplex particle con-
tains f 105 cationic lipids, whereas an SPLP containing 6
mol% cationic lipid contains only f 3 103 cationic lipids.
In summary the results presented here demonstrate that
cationic PEG lipid can be post-inserted into SPLP, resulting
in well-defined SPLP-CPL4 systems that exhibit improved
uptake into BHK cells in vitro. In the presence of Ca2 +,SPLP-CPL4 systems give rise to transfection potencies that
are increased by up to 106-fold as compared to SPLP in the
absence of Ca2 +. These results indicate that the SPLP system
is a highly transfection potent entity following uptake into
cells and suggest methods for improving the properties of
SPLP for systemic gene therapy applications.Acknowledgements
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